Table 2.
Comparison Between Recurrent and No Recurrent Cases.
| Variable | Recurrence (+) (n = 13) | Recurrence (−) (n = 12) | P-value |
|---|---|---|---|
| Age (year) | |||
| Mean (SD) | 64.8 ± 12.4 | 69.7 ± 9.2 | .2754 |
| Sex | |||
| Male | 13 | 11 | .2881 |
| Female | 0 | 1 | |
| Hepatic virus | |||
| HBV | 7 | 3 | .3237 |
| HCV | 1 | 1 | |
| NBNC | 5 | 8 | |
| Albumin (g/dL) | |||
| Mean (SD) | 4.1 ± 0.4 | 4.3 ± 0.3 | .2626 |
| Total bilirubin (mg/dL) | |||
| Mean (SD) | 0.6 ± 0.1 | 0.7 ± 0.1 | .01 |
| ICGR15 (%) | |||
| Mean (SD) | 11.5 ± 5.7 | 9.8 ± 6.0 | .4752 |
| NLR | |||
| Mean (SD) | 2.8 ± 1.5 | 3.3 ± 3.2 | .5923 |
| SII | |||
| Mean (SD) | 539.6 ± 318.3 | 734.1 ± 840.7 | .445 |
| PNI | |||
| Mean (SD) | 48.9 ± 6.2 | 50.8 ± 4.4 | .3921 |
| Size (mm) | |||
| Mean (SD) | 95.1 ± 35.6 | 75.4 ± 8.8 | .1182 |
| Number | |||
| Solitary | 9 | 11 | .1612 |
| Multiple | 4 | 1 | |
| Stage | |||
| II | 7 | 10 | .1143 |
| III | 6 | 2 | |
| BCLC stage | |||
| B | 13 | 12 | NA |
| AFP (ng/mL) | |||
| Mean (SD) | 59 278.3 ± 136 068.7 | 75.4 ± 177.4 | .146 |
| PIVKA-II (mAU/mL) | |||
| Mean (SD) | 20 515.1 ± 40 087.3 | 983.0 ± 1784.1 | .1058 |
| AP-factor | |||
| Low | 4 | 9 | .027 |
| High | 9 | 3 | |
| Child–Pugh | |||
| A | 13 | 12 | NA |
| Differentiation | |||
| Well | 7 | 7 | .5061 |
| Moderate | 6 | 4 | |
| Poor | 0 | 1 | |
| Vascular invasion | |||
| vp+ | 11 | 9 | .5482 |
| vp− | 2 | 3 | |
| vv+ | 6 | 11 | .0148 |
| vv− | 7 | 1 | |
| Fibrosis 22 | |||
| F0 | 2 | 3 | .052 |
| F1 | 2 | 7 | |
| F2 | 7 | 2 | |
| F3 | 2 | 0 | |
HBV, hepatitis B virus surface antigen-positive, hepatitis C virus antibody-negative; HCV, hepatitis B virus surface antigen negative, hepatitis C virus antibody-positive; NBNC, hepatitis B virus surface antigen negative, hepatitis C virus antibody-negative; ICGR15, indocyanine green retention rate at 15 minutes; NLR, neutrophil-to-lymphocyte ratio; SII, systemic immune-inflammation index; PNI, prognostic nutritional index; BCLC stage, Barcelona clinic liver cancer staging classification; AFP, alpha-fetoprotein; PIVKA-II, protein induced by vitamin K absence or antagonist II; AP-factor, AFP × PIVKA-II; vp, microscopic tumor thrombus in the portal vein; vv, microscopic tumor thrombus in the hepatic vein; F0, absence of fibrosis; F1, portal fibrosis with no septa; F2, portal fibrosis with infrequent septa; F3, numerous septa but no cirrhosis; SD, standard deviation; NA, not applicable.